Specialty pharmaceutical company, Neuraxpharm, is expanding its operations in Southern Europe with the launch of Neuraxpharm Portugal.
Based in Lisbon, Neuraxpharm Portugal will be part of the Company’s Southern European Region that comprises Italy, Spain and now Portugal.
Neuraxpharm said it aims to build its position as a central nervous system (CNS) specialist in Portugal offering its wide portfolio of branded and consumer healthcare products in the Portuguese market for the first time.
Neuraxpharm will therefore leverage its industry networks and CNS expertise to make its extensive portfolio available to patients. The company is planning the first commercial launch in December this year with a probiotic product.
Teng Dias has been appointed as Commercial Director of the Portugal business. He previously held senior positions at Baldacci and Sanofi-Aventis, among others.
“Neuraxpharm Portugal demonstrates our ambition to be a leading CNS player across Europe. Portugal is an exciting market with a potential of over EUR 500 million in CNS,” said CEO Jörg-Thomas Dierks.